{"transactions":[{"id":1157497,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-05-06T16:40:24.000Z","date":"2025-05-02","kind":"sale","planned":false,"acquired":false,"shares":4616,"price":11.03,"value":50914.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the disposition of shares that were sold to pay withholding taxes upon vesting of 13,099 restricted stock units."}],"balance_after":49169,"source":{"system":"sec-edgar","filing":"0001127602-25-013484","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760225013484/form4.xml","form_type":"4"}},{"id":1212586,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-03-11T16:28:27.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":2565,"price":13.5971,"value":34876.5615,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the disposition of shares that were sold to pay withholding taxes upon vesting of 6,544 restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan: 1,235 shares acquired on June 10, 2024."}],"balance_after":53785,"source":{"system":"sec-edgar","filing":"0001127602-25-009072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760225009072/form4.xml","form_type":"4"}},{"id":1528681,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-05-03T16:06:42.000Z","date":"2024-05-02","kind":"sale","planned":false,"acquired":false,"shares":4745,"price":23.5768,"value":111871.916,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the disposition of shares that were sold to pay withholding taxes upon vesting of 13,098 restricted stock units."}],"balance_after":55115,"source":{"system":"sec-edgar","filing":"0001127602-24-014115","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760224014115/form4.xml","form_type":"4"}},{"id":1589398,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Stock Options","published_at":"2024-03-07T16:09:08.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":117801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest on the one year anniversary of March 5, 2024 (the \"Vesting Commencement Date\") and 1/48th of the shares shall vest monthly thereafter, such that the option shall be fully vested on the four year anniversary of the Vesting Commencement Date."}],"balance_after":117801,"derivative":{"exercise_price":22.85,"expiration_date":"2034-03-04","underlying":"Common Stock","underlying_shares":117801},"source":{"system":"sec-edgar","filing":"0001127602-24-009004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760224009004/form4.xml","form_type":"4"}},{"id":1589397,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-07T16:09:08.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":19634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest as follows: 1/3 of the shares vest on the first, second and third anniversaries of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following shares acquired by the reporting person pursuant to the Issuer's Employee Stock Purchase Plan: 930 shares acquired in December 2023."}],"balance_after":59860,"source":{"system":"sec-edgar","filing":"0001127602-24-009004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760224009004/form4.xml","form_type":"4"}},{"id":1906422,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Stock Options","published_at":"2023-05-03T20:48:54.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":235778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest on the one year anniversary of May 1, 2024 (the \"Vesting Commencement Date\") and 1/48th of the shares shall vest monthly thereafter, such that the option\nshall be fully vested on the four year anniversary of the Vesting Commencement Date."}],"balance_after":235778,"derivative":{"exercise_price":27.07,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":235778},"source":{"system":"sec-edgar","filing":"0001127602-23-014376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760223014376/form4.xml","form_type":"4"}},{"id":1906421,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"officer":true,"officer_title":"EVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-05-03T20:48:54.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":39296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest as follows: 1/3 of the shares vest on the first, second and third anniversaries of the date of grant."}],"balance_after":39296,"source":{"system":"sec-edgar","filing":"0001127602-23-014376","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760223014376/form4.xml","form_type":"4"}},{"id":1959085,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T09:32:52.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":36892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the options vested and became exercisable on November 5, 2022, with the balance of the options vesting in eight equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":22.71,"expiration_date":"2031-11-04","underlying":"Common Shares","underlying_shares":36892},"source":{"system":"sec-edgar","filing":"0001209191-23-017724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000120919123017724/doc4.xml","form_type":"4"}},{"id":1959084,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-03-10T09:32:52.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":3673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the vested portion of 9,859 restricted stock units (\"RSUs\") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the \"Effective Time\") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the \"Per Share Consideration\"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the \"RSU Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-017724","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000120919123017724/doc4.xml","form_type":"4"}},{"id":2130474,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-10-28T16:34:33.000Z","date":"2022-10-26","kind":"grant","acquired":true,"shares":9859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person as the annual non-employee director grant.  The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the \"Merger Agreement\")."}],"balance_after":9859,"source":{"system":"sec-edgar","filing":"0001209191-22-054810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000120919122054810/doc4.xml","form_type":"4"}},{"id":2162444,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-09T16:22:18.000Z","date":"2022-09-08","kind":"grant","acquired":true,"shares":35282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option vest and become exercisable on September 8, 2023, and the remaining shares vest in equal monthly installments over the subsequent 24 months."}],"balance_after":35282,"derivative":{"exercise_price":25.32,"expiration_date":"2032-09-08","underlying":"Common Stock","underlying_shares":35282},"source":{"system":"sec-edgar","filing":"0001127602-22-022254","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000112760222022254/form4.xml","form_type":"4"}},{"id":2519970,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":80098,"kind":"person","name":"Valente Nancy","position":1,"cik":"0001891344","reported_name":"Valente Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-09T17:15:43.000Z","date":"2021-11-05","kind":"grant","acquired":true,"shares":36892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option vest and become exercisable on November 5, 2022, with the balance of the shares vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":36892,"derivative":{"exercise_price":22.71,"expiration_date":"2031-11-04","underlying":"Common Shares","underlying_shares":36892},"source":{"system":"sec-edgar","filing":"0001209191-21-063665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1891344/000120919121063665/doc4.xml","form_type":"4"}}]}